|
"cubillo a"的相關文件
顯示項目 1-8 / 8 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2019-01 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Hubner, RA;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2017-05 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis
|
Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, MF;Yang, Y;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2016-12 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1
|
Hubner, R;Cubillo, A;Blanc, JF;Melisi, D;von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, F;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b
|
Siveke, JT;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, F;Hubner, R |
| 國家衛生研究院 |
2016-10 |
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge
|
Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, M;Yang, Y;de Jong, F;Hubner, R |
| 國家衛生研究院 |
2016-06 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
|
Hubner, R;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, D;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;De Jong, F;Siveke, J |
| 國家衛生研究院 |
2016-05 |
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with
|
Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, M;Yang, Y;de Jong, F;Hubner, R |
| 國家衛生研究院 |
2014-05 |
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad
|
Denlinger, CS;Sym, SJ;Bendell, JC;Alsina, M;Watkins, D;Chao, Y;Cubillo, A;Kunz, PL;Sun, WJ;Baeksgaard, L;Chen, LT;Horgan, K;Frye, S;Kudia, AJ;McDonagh, CF;Czibere, AG;Moyo, VM;Chibaudel, B;Bang, YJ |
顯示項目 1-8 / 8 (共1頁)
1
每頁顯示[10|25|50]項目
|
